SARS COV-2 Infection in an Allergic Asthma Patient Taking Omalizumab: A Case Report

Authors : Ümmügülsüm Dikici, Öner Özdemir

Pages : 66-70

Doi:10.34084/bshr.1395577

View : 38 | Download : 28

Publication Date : 2024-04-30

Article Type : Other Papers

Abstract :In March 2020, the World Health Organization declared a pandemic due to the coronavirus disease (COVID-19) caused by the SARS-CoV-2 virus affecting the respiratory tract. Comorbid diseases with severe lung involvement were defined for this infection. Due to its multifactorial pathophysiology, asthma has become one of the most curious, researched, and controversial diseases with comorbidity. The relationship between viral load and disease symptoms of biological agents, which are becoming more important and increasingly used in treating chronic diseases, is being investigated. Omalizumab is a human anti-immunoglobulin E (IgE) antibody approved for asthma and chronic urticaria use. We present the course of COVID-19 disease in a 20-year-old patient with allergic asthma whose asthma symptoms were under control with omalizumab for one year. Our patient had an outpatient course for COVID-19 without developing a cough or other asthma attack symptoms and without hospitalization. By presenting this case, we would like to emphasize that omalizumab treatment during COVID-19 disease does not affect the course of the disease.
Keywords : astım, COVID 19, omalizumab